Forta Bio

Forta Bio is a next-generation biotech company developing precision therapies that selectively eliminate disease-driving immune and cancer cells — without compromising healthy immunity. Our proprietary cell targeting 6tdGO DNA platform uses a dual mechanism of action to directly disrupt telomeres in specific TERT+ cells while activating the body’s immune response. This approach is uniquely suited for treating aggressive cancers and autoimmune diseases. We focus on high-burden, underserved conditions — particularly those affecting women and children — and pursue accelerated regulatory pathways. Backed by validated science from City of Hope and led by a team with 7+ INDs, 30+ pharma deals, and multiple biotech exits, Forta Bio is on a mission to bring smarter, safer, and more targeted therapies to patients who need them most.